世界の原発性胆汁性胆管炎治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Primary Biliary Cholangitis Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4763
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、96ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、原発性胆汁性胆管炎治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オカリバ、ウルソジオール、その他）、用途別市場規模（病院、私立クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・原発性胆汁性胆管炎治療薬の市場動向
・企業の競争状況、市場シェア
・原発性胆汁性胆管炎治療薬の種類別市場規模と予測2016-2027（オカリバ、ウルソジオール、その他）
・原発性胆汁性胆管炎治療薬の用途別市場規模と予測2016-2027（病院、私立クリニック、その他）
・原発性胆汁性胆管炎治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・原発性胆汁性胆管炎治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・原発性胆汁性胆管炎治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・原発性胆汁性胆管炎治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・原発性胆汁性胆管炎治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Abbott Laboratories、Allergan Plc、Eli Lilly and Co.、Intercept Pharmaceuticals Inc.、Takeda Pharmaceutical Co. Ltd.）
・結論

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.
There is a dire need for curative therapy for primary biliary cholangitis across the world. This is because of the recurring nature of the disease. Currently, the only cure for the condition is a liver transplant. This method of treatment makes it difficult for patients to lead a normal life even with post-surgery treatment. This has resulted in research on stem cell transplantation to replace destroyed cells in the bile duct.

Market Analysis and Insights: Global Primary Biliary Cholangitis Therapeutics Market
The global Primary Biliary Cholangitis Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Primary Biliary Cholangitis Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Primary Biliary Cholangitis Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Primary Biliary Cholangitis Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Primary Biliary Cholangitis Therapeutics market.

Global Primary Biliary Cholangitis Therapeutics Scope and Market Size
Primary Biliary Cholangitis Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Primary Biliary Cholangitis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
OCALIVA
Ursodiol
Others

Segment by Application
Hospital
Private Clinic
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott Laboratories
Allergan Plc
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Takeda Pharmaceutical Co. Ltd.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 OCALIVA
1.2.3 Ursodiol
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Biliary Cholangitis Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Private Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Primary Biliary Cholangitis Therapeutics Market Perspective (2016-2027)
2.2 Primary Biliary Cholangitis Therapeutics Growth Trends by Regions
2.2.1 Primary Biliary Cholangitis Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Primary Biliary Cholangitis Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Primary Biliary Cholangitis Therapeutics Industry Dynamic
2.3.1 Primary Biliary Cholangitis Therapeutics Market Trends
2.3.2 Primary Biliary Cholangitis Therapeutics Market Drivers
2.3.3 Primary Biliary Cholangitis Therapeutics Market Challenges
2.3.4 Primary Biliary Cholangitis Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Primary Biliary Cholangitis Therapeutics Players by Revenue
3.1.1 Global Top Primary Biliary Cholangitis Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Primary Biliary Cholangitis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Primary Biliary Cholangitis Therapeutics Revenue
3.4 Global Primary Biliary Cholangitis Therapeutics Market Concentration Ratio
3.4.1 Global Primary Biliary Cholangitis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Biliary Cholangitis Therapeutics Revenue in 2020
3.5 Primary Biliary Cholangitis Therapeutics Key Players Head office and Area Served
3.6 Key Players Primary Biliary Cholangitis Therapeutics Product Solution and Service
3.7 Date of Enter into Primary Biliary Cholangitis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Primary Biliary Cholangitis Therapeutics Breakdown Data by Type
4.1 Global Primary Biliary Cholangitis Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Type (2022-2027)

5 Primary Biliary Cholangitis Therapeutics Breakdown Data by Application
5.1 Global Primary Biliary Cholangitis Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Primary Biliary Cholangitis Therapeutics Market Size (2016-2027)
6.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Type
6.2.1 North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2027)
6.3 North America Primary Biliary Cholangitis Therapeutics Market Size by Application
6.3.1 North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2027)
6.4 North America Primary Biliary Cholangitis Therapeutics Market Size by Country
6.4.1 North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Primary Biliary Cholangitis Therapeutics Market Size (2016-2027)
7.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type
7.2.1 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2027)
7.3 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application
7.3.1 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2027)
7.4 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country
7.4.1 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Type
8.2.1 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Application
8.3.1 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Region
8.4.1 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Primary Biliary Cholangitis Therapeutics Market Size (2016-2027)
9.2 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type
9.2.1 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application
9.3.1 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country
9.4.1 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Type
10.2.1 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Application
10.3.1 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Country
10.4.1 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Introduction
11.1.4 Abbott Laboratories Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
11.1.5 Abbott Laboratories Recent Development
11.2 Allergan Plc
11.2.1 Allergan Plc Company Details
11.2.2 Allergan Plc Business Overview
11.2.3 Allergan Plc Primary Biliary Cholangitis Therapeutics Introduction
11.2.4 Allergan Plc Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
11.2.5 Allergan Plc Recent Development
11.3 Eli Lilly and Co.
11.3.1 Eli Lilly and Co. Company Details
11.3.2 Eli Lilly and Co. Business Overview
11.3.3 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Introduction
11.3.4 Eli Lilly and Co. Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
11.3.5 Eli Lilly and Co. Recent Development
11.4 Intercept Pharmaceuticals Inc.
11.4.1 Intercept Pharmaceuticals Inc. Company Details
11.4.2 Intercept Pharmaceuticals Inc. Business Overview
11.4.3 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Introduction
11.4.4 Intercept Pharmaceuticals Inc. Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
11.4.5 Intercept Pharmaceuticals Inc. Recent Development
11.5 Takeda Pharmaceutical Co. Ltd.
11.5.1 Takeda Pharmaceutical Co. Ltd. Company Details
11.5.2 Takeda Pharmaceutical Co. Ltd. Business Overview
11.5.3 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Introduction
11.5.4 Takeda Pharmaceutical Co. Ltd. Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
11.5.5 Takeda Pharmaceutical Co. Ltd. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of OCALIVA
Table 3. Key Players of Ursodiol
Table 4. Key Players of Others
Table 5. Global Primary Biliary Cholangitis Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Primary Biliary Cholangitis Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Primary Biliary Cholangitis Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Primary Biliary Cholangitis Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Primary Biliary Cholangitis Therapeutics Market Share by Regions (2022-2027)
Table 11. Primary Biliary Cholangitis Therapeutics Market Trends
Table 12. Primary Biliary Cholangitis Therapeutics Market Drivers
Table 13. Primary Biliary Cholangitis Therapeutics Market Challenges
Table 14. Primary Biliary Cholangitis Therapeutics Market Restraints
Table 15. Global Primary Biliary Cholangitis Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Primary Biliary Cholangitis Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Primary Biliary Cholangitis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Biliary Cholangitis Therapeutics as of 2020)
Table 18. Ranking of Global Top Primary Biliary Cholangitis Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Primary Biliary Cholangitis Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Primary Biliary Cholangitis Therapeutics Product Solution and Service
Table 22. Date of Enter into Primary Biliary Cholangitis Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Primary Biliary Cholangitis Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Abbott Laboratories Company Details
Table 63. Abbott Laboratories Business Overview
Table 64. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product
Table 65. Abbott Laboratories Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Abbott Laboratories Recent Development
Table 67. Allergan Plc Company Details
Table 68. Allergan Plc Business Overview
Table 69. Allergan Plc Primary Biliary Cholangitis Therapeutics Product
Table 70. Allergan Plc Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Allergan Plc Recent Development
Table 72. Eli Lilly and Co. Company Details
Table 73. Eli Lilly and Co. Business Overview
Table 74. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product
Table 75. Eli Lilly and Co. Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Eli Lilly and Co. Recent Development
Table 77. Intercept Pharmaceuticals Inc. Company Details
Table 78. Intercept Pharmaceuticals Inc. Business Overview
Table 79. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product
Table 80. Intercept Pharmaceuticals Inc. Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Intercept Pharmaceuticals Inc. Recent Development
Table 82. Takeda Pharmaceutical Co. Ltd. Company Details
Table 83. Takeda Pharmaceutical Co. Ltd. Business Overview
Table 84. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Product
Table 85. Takeda Pharmaceutical Co. Ltd. Revenue in Primary Biliary Cholangitis Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Takeda Pharmaceutical Co. Ltd. Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Biliary Cholangitis Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. OCALIVA Features
Figure 3. Ursodiol Features
Figure 4. Others Features
Figure 5. Global Primary Biliary Cholangitis Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Private Clinic Case Studies
Figure 8. Other Case Studies
Figure 9. Primary Biliary Cholangitis Therapeutics Report Years Considered
Figure 10. Global Primary Biliary Cholangitis Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Primary Biliary Cholangitis Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Primary Biliary Cholangitis Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Primary Biliary Cholangitis Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Primary Biliary Cholangitis Therapeutics Market Share by Players in 2020
Figure 15. Global Top Primary Biliary Cholangitis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Biliary Cholangitis Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Primary Biliary Cholangitis Therapeutics Revenue in 2020
Figure 17. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Primary Biliary Cholangitis Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Primary Biliary Cholangitis Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Primary Biliary Cholangitis Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Primary Biliary Cholangitis Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Primary Biliary Cholangitis Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Primary Biliary Cholangitis Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Share by Region (2016-2027)
Figure 39. China Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Primary Biliary Cholangitis Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Primary Biliary Cholangitis Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Primary Biliary Cholangitis Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Abbott Laboratories Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
Figure 59. Allergan Plc Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
Figure 60. Eli Lilly and Co. Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
Figure 61. Intercept Pharmaceuticals Inc. Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
Figure 62. Takeda Pharmaceutical Co. Ltd. Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

以下、関連資料のご紹介

世界の原発性硬化性胆管炎治療市場規模・現状・予測（2021年-2027年）

Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4765 2021年6月 129Pages
QYResearch社発行の本調査レポートでは、原発性硬化性胆管炎治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（肝移植手術、UDCA薬、PSC薬）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、...

世界の胆管腫瘍市場規模・現状・予測（2021年-2027年）

Global Biliary Tumor Market Size, Status and Forecast 2021-2027
QFJ1-5618 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、胆管腫瘍の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、手術、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南...

世界の胆道閉鎖症治療市場規模・現状・予測（2021年-2027年）

Global Biliary Atresia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3899 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、胆道閉鎖症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、手術治療）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、...

世界の胆道障害治療市場規模・現状・予測（2021年-2027年）

Global Biliary Tract Disorder Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5617 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、胆道障害治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、手術、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、...

世界のCOPD治療薬市場規模・現状・予測（2021年-2027年）

Global COPD Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-5676 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、COPD治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（気管支拡張薬、吸入コルチコステロイド、その他）、用途別市場規模（大人用、子供用）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、...

世界の未分化甲状腺がん治療薬市場規模・現状・予測（2021年-2027年）

Global Anaplastic Thyroid Cancer Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-3802 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、未分化甲状腺がん治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（病院、薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東...

世界のアトピー性皮膚炎治療薬市場規模・現状・予測（2021年-2027年）

Global Atopic Dermatitis Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-3867 2021年6月 85Pages
QYResearch社発行の本調査レポートでは、アトピー性皮膚炎治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（外用剤、全身療法）、用途別市場規模（大人用、子供用）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、...

世界のアテローム性動脈硬化症治療薬市場規模・現状・予測（2021年-2027年）

Global Atherosclerosis Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-5602 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、アテローム性動脈硬化症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（小分子、生物製剤）、用途別市場規模（病院、診療所、研究機関、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本...

世界の抗菌治療薬市場規模・現状・予測（2021年-2027年）

Global Antimicrobial Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-5586 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、抗菌治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（病院、診療所、個人、その他）、用途別市場規模（抗ウイルス剤、抗菌剤、抗真菌剤、駆虫剤）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本...

世界の脾腫治療薬市場規模・現状・予測（2021年-2027年）

Global Splenomegaly Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-6019 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、脾腫治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬物療法、予防接種、その他）、用途別市場規模（正常（非脾腫）、中等度脾腫、重度脾腫）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、...

世界の原発性硬化性胆管炎治療市場規模・現状・予測（2021年-2027年） Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases.The disease is characterized by inflammation and thickening of the bile ducts.This impedes bile flow and may lead to other liver diseases.Primary sclerosing cholangitis (PSC) is treated in a…
世界の胆道閉鎖症治療市場規模・現状・予測（2021年-2027年） Biliary atresia or extra hepatic ductopenia is an acquired disease of the liver. This disease is characterized by the obliteration of the extra hepatic biliary system which results in obstruction of the bile flow from the liver to gall bladder. Market Analysis and Insights: Global Biliary Atresia Tr…
世界の胆管腫瘍市場規模・現状・予測（2021年-2027年） Biliary Tumor is a form of cancer that develops in the bile duct system, which connects the liver, gallbladder, and small intestine, moving bile – a fluid that helps digest fats – to the small intestine. Market Analysis and Insights: Global Biliary Tumor Market The global Biliary Tumor market size i…
胆道閉鎖症治療のグローバル市場：規模・現状・予測2019-2025 Biliary atresia or extra hepatic ductopenia is an acquired disease of the liver. This disease is characterized by the obliteration of the extra hepatic biliary system which results in obstruction of the bile flow from the liver to gall bladder.In 2018, the global Biliary Atresia Treatment market siz…
胆道閉鎖症治療のグローバル市場：規模・現状・予測2019-2025 Biliary atresia or extra hepatic ductopenia is an acquired disease of the liver. This disease is characterized by the obliteration of the extra hepatic biliary system which results in obstruction of the bile flow from the liver to gall bladder.In 2018, the global Biliary Atresia Treatment market siz…